Logo image of GNFT.PA

GENFIT (GNFT.PA) Stock Fundamental Analysis

Europe - EPA:GNFT - FR0004163111 - Common Stock

3.7 EUR
+0.06 (+1.54%)
Last: 10/17/2025, 7:00:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to GNFT. GNFT was compared to 81 industry peers in the Biotechnology industry. While GNFT seems to be doing ok healthwise, there are quite some concerns on its profitability. GNFT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year GNFT has reported negative net income.
GNFT had a negative operating cash flow in the past year.
In multiple years GNFT reported negative net income over the last 5 years.
In multiple years GNFT reported negative operating cash flow during the last 5 years.
GNFT.PA Yearly Net Income VS EBIT VS OCF VS FCFGNFT.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

1.2 Ratios

With a Return On Assets value of -17.89%, GNFT perfoms like the industry average, outperforming 55.56% of the companies in the same industry.
The Return On Equity of GNFT (-73.87%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -17.89%
ROE -73.87%
ROIC N/A
ROA(3y)-8.87%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GNFT.PA Yearly ROA, ROE, ROICGNFT.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

In the last couple of years the Profit Margin of GNFT has declined.
GNFT's Operating Margin has declined in the last couple of years.
GNFT has a better Gross Margin (95.42%) than 91.36% of its industry peers.
In the last couple of years the Gross Margin of GNFT has remained more or less at the same level.
GNFT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.42%
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
GNFT.PA Yearly Profit, Operating, Gross MarginsGNFT.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

More info and screens

4

2. Health

2.1 Basic Checks

GNFT does not have a ROIC to compare to the WACC, probably because it is not profitable.
GNFT has more shares outstanding than it did 1 year ago.
GNFT has more shares outstanding than it did 5 years ago.
GNFT has a worse debt/assets ratio than last year.
GNFT.PA Yearly Shares OutstandingGNFT.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
GNFT.PA Yearly Total Debt VS Total AssetsGNFT.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

GNFT has an Altman-Z score of -1.49. This is a bad value and indicates that GNFT is not financially healthy and even has some risk of bankruptcy.
GNFT's Altman-Z score of -1.49 is on the low side compared to the rest of the industry. GNFT is outperformed by 64.20% of its industry peers.
GNFT has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.09, GNFT is in the better half of the industry, outperforming 61.73% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z -1.49
ROIC/WACCN/A
WACC7.38%
GNFT.PA Yearly LT Debt VS Equity VS FCFGNFT.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

GNFT has a Current Ratio of 3.74. This indicates that GNFT is financially healthy and has no problem in meeting its short term obligations.
GNFT has a Current ratio of 3.74. This is in the better half of the industry: GNFT outperforms 66.67% of its industry peers.
A Quick Ratio of 3.74 indicates that GNFT has no problem at all paying its short term obligations.
GNFT has a better Quick ratio (3.74) than 67.90% of its industry peers.
Industry RankSector Rank
Current Ratio 3.74
Quick Ratio 3.74
GNFT.PA Yearly Current Assets VS Current LiabilitesGNFT.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

2

3. Growth

3.1 Past

GNFT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -327.32%.
Measured over the past years, GNFT shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -70.77% on average per year.
Looking at the last year, GNFT shows a very negative growth in Revenue. The Revenue has decreased by -45.94% in the last year.
The Revenue has been growing by 11.61% on average over the past years. This is quite good.
EPS 1Y (TTM)-327.32%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-139.82%
Revenue 1Y (TTM)-45.94%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-39.51%

3.2 Future

Based on estimates for the next years, GNFT will show a very negative growth in Earnings Per Share. The EPS will decrease by -29.26% on average per year.
GNFT is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -2.23% yearly.
EPS Next Y15.82%
EPS Next 2Y-94%
EPS Next 3Y-41.45%
EPS Next 5Y-29.26%
Revenue Next Year-8.28%
Revenue Next 2Y-21.93%
Revenue Next 3Y-9.85%
Revenue Next 5Y-2.23%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
GNFT.PA Yearly Revenue VS EstimatesGNFT.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M 200M
GNFT.PA Yearly EPS VS EstimatesGNFT.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GNFT. In the last year negative earnings were reported.
Also next year GNFT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GNFT.PA Price Earnings VS Forward Price EarningsGNFT.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GNFT.PA Per share dataGNFT.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

A cheap valuation may be justified as GNFT's earnings are expected to decrease with -41.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-94%
EPS Next 3Y-41.45%

More info and screens

0

5. Dividend

5.1 Amount

GNFT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENFIT

EPA:GNFT (10/17/2025, 7:00:00 PM)

3.7

+0.06 (+1.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-22 2025-09-22
Earnings (Next)11-20 2025-11-20
Inst Owners0.76%
Inst Owner ChangeN/A
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap185.01M
Analysts90.77
Price Target8.93 (141.35%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.85%
PT rev (3m)-6.91%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-24.55%
EPS NY rev (3m)722.47%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-2.18%
Revenue NY rev (3m)-11.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.07
P/FCF N/A
P/OCF N/A
P/B 3.53
P/tB 87.02
EV/EBITDA N/A
EPS(TTM)-0.77
EYN/A
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0.91
BVpS1.05
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.89%
ROE -73.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.42%
FCFM N/A
ROA(3y)-8.87%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
F-Score2
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 188.46%
Cap/Sales 7.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.74
Quick Ratio 3.74
Altman-Z -1.49
F-Score2
WACC7.38%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-327.32%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-139.82%
EPS Next Y15.82%
EPS Next 2Y-94%
EPS Next 3Y-41.45%
EPS Next 5Y-29.26%
Revenue 1Y (TTM)-45.94%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-39.51%
Revenue Next Year-8.28%
Revenue Next 2Y-21.93%
Revenue Next 3Y-9.85%
Revenue Next 5Y-2.23%
EBIT growth 1Y-216.85%
EBIT growth 3Y-53.58%
EBIT growth 5YN/A
EBIT Next Year-6.17%
EBIT Next 3Y-0.9%
EBIT Next 5YN/A
FCF growth 1Y87.25%
FCF growth 3Y-47.27%
FCF growth 5YN/A
OCF growth 1Y93.33%
OCF growth 3Y-46.21%
OCF growth 5YN/A